Last Updated on January 30, 2023
- Survey of 720 healthcare providers (HCPs) on their evolving needs due to COVID-19 and how pharmaceutical companies can best engage with them.
- Participants identified themselves as one of the following healthcare disciplines: general practitioner, oncologist, immunologist or cardiologist.
- Three key findings reveal an opportunity for pharma companies to gain time, trust and influence with HCPs and their patients.
- Pharma companies should seize this opportunity to test bold new ways of thinking and working.
